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Summary A systematic review of the literature was undertaken to assess what published evidence
is currentlyavailable to support the increasing use of autologous stem cell transplantation
(ASCT), and to evaluate the published data with regard to the comparative cost of high-
dose and conventional therapy. The review aimed to identify all published, randomized
controlled trials (RCTs) comparing high-dose therapy (HDT) with ASCT versus
conventional chemotherapy (CC) in acute lymphoblastic leukaemia, non-Hodgkin's
lymphoma, Hodgkin's disease, multiple myeloma, and breast, lung, testicular and ovarian
cancer.The reviewalsoaimed toidentifyall studiesthat had comparedthe costof thetwo
treatment strategies. Reports were identi¢ed by systematic searches of Cancerlit, Embase
and Medline, and handsearching of several conference proceedings. Where possible,
pooled odds ratios (ORs) were calculated according to the ¢xed-e¡ect model. A total of18
randomized trials were identi¢ed in acute lymphoblastic leukaemia, non-Hodgkin's
lymphoma, Hodgkin's disease, multiple myeloma, and breast, lung and testicular cancer.
Trials were generally small and no disease site had su¤cient information to determine
reliably whether high-dose therapy with autologous transplant is more e¡ective than CC.
Five studies were identi¢ed that compared the cost of the two treatments.These found the
cost of HDT to be between one and four times higher thanthat of CC. Further randomized
trials are required. Where appropriate, these should include economic assessment and
assessmentsof long-termtoxicity.
Keywords Autologousstemcelltransplantation,high-dosetherapy,conventionalchemotherapy
Introduction
Theuseofhigh-dosetherapy(HDT)employingmyeloabla-
tive treatment and haematopoietic rescue is increasing in
both haematological and non-haematological malignan-
cies.DatafromtheInternationalBoneMarrowTransplan-
tation Registry and the Autologous Blood and Bone
Marrow Transplant Registry estimated that around 500
autologoustransplantswereperformedworldwidein1970
(Horowitz&Rowlings1997)withthis¢gurerisingtoover
17,000in1995.Thefactorsbehindthisincreasehavebeen
widely discussed, and relate to the unsatisfactory results
of conventional treatment, reports of dose^response rela-
tionshipsforsomemalignancies(atleastinvitro),encoura-
ging reports from single institutions and registry-based
series ,to g eth erwithr ed u ctio nsinm or b idi tyo win gtoth e
use of growth factor-mobilized haemopoietic progenitors
and improvements in supportive care.Thesehave encour-
agedtheuseofprogenitorcelltransplantsinthetreatment
ofanumberofdiseaseswheretherisksoftherapywerepre-
viouslythoughttooutweighthepotentialbene¢ts.
Despite several thousand publications reporting the
results of transplant series, there is stillgreat uncertainty 61
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#2000BlackwellScienceLimitedas to the true e¡ectiveness of HDT and progenitor cell
transplants. The treatment is often viewed as expensive
andtoxic.Asystematicreviewoftherandomizedliterature
wasthereforeundertaken(Johnsonetal.1998)toevaluate
the e¤cacy of high-dose therapy with autologous trans-
plantation(HDT(autol))comparedwithconventionalche-
motherapy (CC).This reviewas awhole investigated both
autologous andallogeneic transplantation.Thelatteralso
considered evidence from non-randomized controlled
clinical trials because insu¤cient randomized evidence
was available.This paper, however, is restricted tothe evi-
dence relating to autologous transplantation where only
randomized controlled trials were considered.) Results for
acute lymphoblastic leukaemia, malignant lymphoma,
multiple myeloma, breast, lung and testicular cancer are
presented here. No randomized trials were identi¢ed for
chronicmyeloidandchroniclymphocyticleukaemiaorfor
ovariancancer.Thedataonautologoustransplantationin
acutemyeloidleukaemiaarenotreportedbecauseanindi-
vidualpatient data meta-analysis has recentlybeen com-
pleted by the International Acute Myeloid Leukaemia
Collaborative Group (M. Clarke, personal communica-
tion), which will give a more reliable assessment of e¡ec-
tiveness.The disease sites investigated representtheareas
in which most transplant activity has been focused and
where,owingtotheincidenceoftheillnesses,theclinical
andeconomicimpactislikelytobegreatest.Theliterature
onthecomparativecostof HDTandprogenitorcelltrans-
plantationvs.conventionaltherapyhasalsobeensystema-
ticallyreviewedandisincludedinthisreport.
Methods
Themethodsfortrialidenti¢cationandanalysisofresults
were speci¢ed prospectively. Published studies were iden-
ti¢ed using electronic literature searches of Cancerlit,
Embase,MedlineandtheNHSEconomicEvaluationData-
base (completed onJanuary1,1997). A second search for
randomized controlled trials (RCTs) using a modi¢ed ver-
sion of the Cochrane Collaboration optimal search strat-
egy was completed on June 1, 1997. This was
supplemented byhand searchingconferenceproceedings
of the European Bone Marrow Transplantation Group
(1992^97), International Society for ExperimentalHema-
tology (1992^96) and European Haematology Associa-
tion (1994^96). In addition, the UK Coordinating
Committee on Cancer Research Cancer Trials Register
and the National Cancer Institute PDQ database were
searched for reports of eligible ongoing and unpublished
trials, although no additional information was sought
fromthesetrials.
Only randomized trials were included in the analysis.
Tables of non-randomized studies and of ongoing rando-
mizedtrials arepresented elsewhere (Johnson etal.1998).
Randomizationcouldhavebeenatanystageoftheillness,
forexampleas¢rst-linetherapy,consolidationofresponse
or second-line therapy. Studies should also have reported
on overall survival or progression-free survival, where
progression-free survival was de¢ned as patients alive
and progression-free at the time of analysis. There were
no language restrictions and no judgement was made as
to whether the high-dose therapy was truly myeloabla-
tive. For economic comparisons, studies were included if
the report made an economic evaluation of HDT com-
pared with CC. Decisions on the inclusion of potentially
eligible papers, together with data extraction, were car-
ried out independently by two reviewers. Any discrepan-
cies were resolved by discussion and by seeking a third
opinionwherenecessary.
Odds ratios (ORs) were combined using the Peto
method according to the ¢xed-e¡ects model.Where ORs
werenotpresentedinthepaperatthetime-pointsofinter-
est, the statistic was calculated from observed and
expectednumberofeventstakenfromthepaperor calcu-
latedfromsurvivalcurves.In-housesoftwarewasusedto
perform statistical analysis and to produce plots. The w
2-
test for heterogeneity (Early Breast Cancer Trialists' Col-
laborative Group1990) was used to test for gross statisti-
cal heterogeneity between individual trials and the w
2-
test for interaction to test for gross statistical heterogene-
ity between groups of trials. Unless otherwise stated, all
P-valuesareon1degree offreedom.
Results
Acrossallthe disease sitesinvestigated,18 RCTs(Humblet
et al. 1987; Fiere et al. 1990; Fiere et al.1994; Bernasconi
et al. 1992; Chevreau et al. 1993; Linch et al.1 9 9 3 ;A t t a l
et al.1994; Sebban et al.1994; Bezwoda, Seymour & Dan-
sey1995;Fermandet al.1 99 5 ;Ljungmanetal.1995;Philip
et al. 1995; Verdonck et al. 1995; Gisselbrecht et al.1 9 9 6 ;
Martelli et al.1 9 9 6 ;P e t e r set al.1 9 9 6 ;G i a n n iet al.1 9 9 7 ;
Haioun et al.1997; Santini et al.1999) of HDT(autol) ver-
sus conventional therapy were identi¢ed, the majority of
whichused bone marrowasthe source of progenitorcells.
Three trials were inadultacute lymphoblastic leukaemia,
s e v e ni nn o n - H o d g k i n ' sl y m p h o m a ,o n ei nH o d g k i n ' sd i s -
ease,twoin multiple myeloma, three inbreastcancer, one
each in lung cancer and germ-cell tumours, and none in
ovarian cancer, chronic myeloid leukaemia or chronic
lymphocytic leukaemia. The results of individual trials
are summarized in Table1, and Table 2 gives a summary
S.J.Simnettetal.
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63Survival Progression-free survival
Disease
Years of
recruitment
Number
of patients HDT (autol):CC
Statistics
inpaper
Calculated OR
(99% CI) HDT (autol):CC
Statistics
inpaper
CalculatedOR
(99% CI) Comments
No ofongoing
trials
Consolidationof ¢rst
remission inslow responders
Martelliet al. (1996) 88^91 49 73:59
4years
NS 0.56
(0.12^2.61)
4years
7 3:5 2
4years
NS 0.42
(0.09^1.90)
2years
Presenceof mediastinal
mass at diagnosis found
to beapositiveprognostic
factorandthiswasnot
balanced inthe twoarms
(in favourof HDT (autol) arm)
Verdonck et al. (1995) 87^94 69 56 : 85
4years
P0.12 4.17
(1.07^16.24)
4years
43:53
4years
P0.43 1.68
(0.49^5.77)
4years
HDT (autol)
for 2nd or 3rd remission
Philipet al.(1995) 87^94 109 61:38
4years
P0.038 0.41
(0.15^1.11)
4years
46:19
5years
P0.001 0.29
(0.10^0.84)
22/55 patients on HDT (autol)
armreceivedradiotherapy,
only12/54 onCC arm
Hodgkin's disease
Relapsedor resistant
3
Linch et al. (1993) ^ 40 74 : 60
2years
P0.318 0.51
(0.09^2.87)
2years
59 : 21
2years
P0.025 0.2
(0.04^1.02)
2years
Mixture of relapsed/resistant
patients,noindication if this was
balanced betweentreatmentgroups
Follow-upis short
Multiple myeloma 2
Attal et al. (1994) 90^93 204 59^39
4years
P0.03 0.45
(0.22^0.93)
4years
28:16
4years
P0.01 0.50
(0.21^1.20)
4years
26% of HDT (autol) patients
did not receivetreatment, 9
CC patients crossed-over
Fermand et al.(1995) 90^94 153 82:67
2years
P0.28
(0.17^1.16)
2years
0.45 77:47
2years
^0 . 2 8
(0.12^0.66)
40%ofCCpatients
crossed-over
Breast cancer
Advanced/metastatic
14 (all stages)
Bezwodaet al.(1995) 91^93 90 44:3
2years
^0 . 1 0
(0.03^0.35)
2years
^ ^ ^ PoorsurvivalonCCarm
Ljungman et al. (1995) 89^94 9 ^ ^ ^ ^ ^ ^ No further informationgiven
inpaper, patients included ina
non-randomizedcomparision
Peters et al.(1996) 88^95 98 23:38* P0.04* 11:4* P0.008* *Ambiguityastowhether these
valuesare mediansurvival/
progression free survivalvalues
or notand whether the P-values
refer to thelog-ranktest
Germ cell tumours 3
Chevreau et al.(1993) 88^91 104 60:80
2years
P0.08 2.71
(0.95^7.76)
2years
58:70
at median
follow-up
of 24 months
^ ^ Totaldose ofcisplatinthe
sameinbotharms
Small cell lung cancer 3
Humblet et al.(19 8 7 ) 8 0^8 5 4 5 3 0:9
2years
P0.13 0.27
(0.04^1.82)
2years
13:0 P0.002 0.13
(0.01^2.72)
Survival measurefrom1st
dayof induction, progression-
free survival fromtime of
randomization
Ovarian Cancer ^0 3
CC,conventionalchemotherapy;HDT(autol),high-dosetherapy withautologoustransplantation;OR,oddsratio;RCT,randomizedcontrolledtrial.
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4of the available informationand overall results by disease
site.
Acute lymphoblastic leukaemia
Three RCTs (Fiere et al. 1990; 1994; Sebban et al. 1994;
Bernasconi et al.1 9 9 2 ) ,i n c l u d i n g2 1 3p a t i e n t si nt o t a l ,
were identi¢ed. All randomized adult patients in ¢rst
complete remission following induction therapy to
receive HDT or conventional consolidation treatment.
None of the trials reported a di¡erence in survival or pro-
gression-free survival. Owing to incomplete data report-
ing, noquantitativesynthesiswaspossible.
Non-Hodgkin's lymphoma
SevenRCTs(Philipet al.1 99 5 ;V erdoncket al.1 99 5 ;Gissel-
brecht et al.1 9 9 6 ;M artelliet al.1 9 9 6 ;H aiounet al.1 9 9 7 ;
Gianni et al. 1997; Santini et al. 1999) were identi¢ed,
including 1192 patients randomized between 1987 and
1995. All investigated HDT in the treatment of intermedi-
ate- and high-grade lymphoma, but in patients with dif-
fering characteristics or at di¡erent stages in the history
ofthelymphoma.
First-line induction therapy
Three trials (Gisselbrecht et al.1 9 9 6 ;G i a n n iet al.1 9 9 7 ;
Santini et al. 1999) were identi¢ed that investigated the
use of HDT as a component of ¢rst-line therapy, one of
which (Gianni et al. 1997) randomized patients to
immediate versus delayed HDTon relapse.The pooled OR
for survivalat 3/4years for twotrials showed no evidence
of a di¡erence between the two treatments (OR0.77;
95% CI 0.57^1.47; Figure1). Two trials reported on pro-
gression-free survival: one (Gianni et al.1997) reported a
signi¢cant bene¢t for HDT; the other (Gisselbrecht et al.
1996) reported a signi¢cant bene¢t for CC. Insu¤cient
Table 2. Summary of the ¢ndings of randomized controlled trials (RCTs) comparing high-dose therapy with autologous progenitor
celltransplantation(HDT(autol))withconventionaltherapy
Disease
Number
oftrials
Number
ofpatients Summaryof Review¢ndings
Adult acute lymphoblastic leukaemia 3 RCTs 213 Noevidenceofadi¡erenceinoverallsurvivalorprogression-
freesurvival
Chronic myeloid leukaemia 00 ^
Chroniclymphocytic leukaemia 00 ^
Non-Hodgkin's lymphoma
Componentoffront-linechemotherapy 6 RCTs 1183 Noevidenceofaoverallsurvivalorprogression-free survival
di¡erence.
(HDT(autol))mayhavebeengivenas¢rst-linetherapyoras
consolidationofa response)
HDT(autol)for2ndor3rdremission 1 RCT 109 Insu¤cientevidencetodrawconclusions.(Singletrial reported
anoverallsurvivalandprogression-freesurvivaladvantagein
favourof HDT(autol).)
Hodgkin's disease
Relapsedorresistant 1 RCT 40 Insu¤cientevidencetodrawconclusions(Singletrialreported
progressionfreesurvivaladvantagein favourof HDT(autol)
butfoundnoevidenceofanoverallsurvivalbene¢t)
Multiple myeloma 2 RCTs 357 Noevidenceofaoverallsurvivaldi¡erence,possible
progression-freesurvivaladvantageinfavourof HDT(autol)
Breastcancer
Advanced/metastatic 3 RCTs 197 Insu¤cientinformation reportedintrialstoallowquantitative
datasummationorconclusionstobedrawn
Germcell tumours 1 104 Insu¤cientevidencetodrawconclusions.(Singletrial foundno
evidenceofanoverallsurvivalbene¢t.Noinformationon
progression-free survival.)
Smallcell lung cancer 1 45 Insu¤cientevidencetodrawconclusions.(Singletrial reported
progression-freesurvivaladvantageinfavourof HDT
(autol)but found noevidenceofanoverall survivalbene¢t)
Ovariancancer 00 ^
Autologousstemcelltransplantationformalignancy:areview
#2000BlackwellScienceLtd.,Clin.Lab .Haem.,22,61^72
65data were included in the reports to allow summation of
thisdata.
Consolidation of first complete remission
One comparatively large trial (Haioun et al. 1997) was
identi¢ed.This randomized 541patients in ¢rst complete
remission who were de¢ned as poor risk according to the
Coi¤er criteria (Coi¡er1991). No evidence of a di¡erence
in overall survival or progression-free survival was
reported.
Consolidation of first remission in slow responders
Two RCTs (Verdonck et al.1995; Martelli et al.1996) were
identi¢ed that included a total of 118 patients who
responded slowly to ¢rst-line induction therapy. Pooled
ORs for overall survival and progression-free survival at
4years showed no evidence of a di¡erence between treat-
ments, with an ORof1.73 (95% CI 0.08^3.75) for survival
and an OR for progression-free survival of 0.96 (95% CI
0.47^1.99)(Figures1and2,respectively).
Consolidation of first remission ± all trials
Pooling the results of 4years'survival forall trials of con-
solidation of ¢rst remission gave an OR of 1.02 (95% CI
0.74^1.42) (Figure 1). For progression-free survival the
overallORwas 0.86 (95% CI 0.63^1.18) (Figure 2).
Consolidation of second or third remission
One RCT (Philip et al. 1995) was identi¢ed that rando-
mized109patients.Thisreportedasigni¢cantoverallsur-
vivaland progression-free survivaladvantage in favourof
HDT(P 0.038 and P 0.001, respectively; Figures1and
2). However, a greater number of patients (40%) on the
HDT arm received radiotherapy compared with the CC
arm(22%).
Hodgkin's disease
Asingletrial(Linchet al.1993) was identi¢ed that rando-
mized 40 patients resistant to, or relapsed following, ¢rst-
line chemotherapy. The trial reported an advantage in
Figure1. Randomized controlled trials comparing high-dose therapy (HDT)  autologous transplantation versus conventional che-
motherapy(CC) in non-Hodgkin'slymphoma.O-E,observed-expectedevents.
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66favour of HDT for progression-free survival (P 0.025),
butfoundnoevidence ofadi¡erence insurvival.
Multiple myeloma
The two trials identi¢ed (Attal et al. 1994; Fermand et al.
1995) reported on a total of 357 patients randomized
between 1990 and 1994. The pooled OR of 0.68 for 2
years' survival showed no clear evidence of a di¡erence
between treatments (95% CI 0.42^1.10; P0.12; Figure
3),whilstthepooledORof0.39forprogression-free survi-
val at 2years was signi¢cantly in favour of HDT (95% CI
0.25^0.59; P<0.001; Figure 4).
Solid tumours
Breast cancer. Three trials (Bezwoda et al. 1995; Ljung-
man et al.1 9 9 5 ;P e t e r set al. 1996) were identi¢ed that
reported on 197 patients with advanced breast cancer
randomized between 1988 and 1995. Two trials (Ljung-
man et al.1 9 9 5 ;P e t e r set al. 1996) randomized patients
responding to initial chemotherapy, whereas in the third
(Ljungman et al. 1995) no chemotherapy was adminis-
teredprior torandomization.Thelargesttrial (Peters etal.
1996), which randomized patients to immediate versus
HDT(autol) on relapse, reported a signi¢cant survival
bene¢t in favour of CC, but a signi¢cant progression-free
survivalbene¢tinfavourof HDT;nodetailsweregivenas
to the number of patients in the conventional arm who
relapsed and received a late transplant. A second trial
(Ljungman et al.1995) reported no survival statistics and
no progression-free survival data. However, a calculated
OR for survival at 2years was conventionally signi¢cant
in favour of HDT with an ORof 0.10 (99% CI 0.03^0.35; P
<0.001).The useof maintenancetamoxifencouldpoten-
tiallyconfound these results as a greater number of HDT
patients responded to treatment and were therefore
o¡ered tamoxifen. The third trial (Peters et al. 1996),
which randomized only nine patients, stopped early
owing to poor accrual, and reported no survival or pro-
gression-free survival data. Insu¤cient information was
includedinthe reportstoallowdatasummation.
Figure2. Randomized controlled trials comparing high-dose therapy (HDT)  autologous transplantationversus conventional che-
motherapy(CC) in non-Hodgkin'slymphoma.O-E,observed-expectedevents.
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67Testicular cancer. ThesingleRCT(Chevreau et al.1 993)
identi¢ed randomized 114 patients with poor prognosis
metastaticgermcelltumoursbetween1988and1991.The
trial found no evidence of an overall survival or progres-
sion-free survival di¡erence betweenthe two treatments,
although the planned dose of cisplatin, the most active
agentadministered,wasidenticalinbotharmsofthetrial.
Small cell lung cancer. One trial (Humblet et al.
1987) was identi¢ed that randomized 45 patients in
complete remission or partial remission after in-
duction chemotherapy. The trial found no evidence
of a di¡erence in overall survival but reported a progres-
sion-free survival advantage in favour of HDT (P 
0.002).
Figure3. Randomized controlled trials comparing high-dose therapy (HDT)  autologous transplantation versus conventional che-
motherapy(CC) in multiplemyeloma. O-E,observed-expectedevents.
Figure4. Randomized controlled trials comparing high-dose therapy (HDT)  autologous transplantationversus conventional che-
motherapy(CC) in multiplemyeloma. O-E,observed-expectedevents.
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68Economic studies
Only one study (Uyl de Groot et al. 1995) that based its
results on the ¢ndings of an RCT was identi¢ed (Table 3).
This studyevaluated the cost of treating 42 of 69 patients
with non-Hodgkin's lymphoma who were randomized in
a trial of postremission therapy for slow responders (Ver-
donck et al. 1995) (Table1). Twenty-one patients were
treated with HDT and 21 patients with CC. No mention
was made as to how the 42 patients were selected from
the total number randomized. This study concluded that
the average costover the ¢rst 2years of therapy (with dis-
counting at 5%) was US $49,983 for HDTand US $15,285
for CC. This di¡erence in cost was mainly a result of the
additionalcostsincurredduringthetreatmentperiod.
Four non-randomized comparisons were also identi¢ed
(Desch et al. 1 9 9 2 ;H i l l n e r ,S m i t h&D e s c h1 9 9 2 ;H e n o n
et al. 1994; Zaidi, Clarke & Hutchinson 1996) (Table 3),
evaluating the cost in multiple myeloma, non-Hodgkin's
lymphoma, relapsed Hodgkin's disease and breast cancer.
These studies found the cost of HDT to be between one
andfourtimeshigherthanthecostofCC.
Discussion
HDT with autologous stem cell transplantation has been
under investigation for over 30 years and, for some dis-
eases, has become established as a routine component of
treatment. Despite the publication of hundreds of case
seriesandcohort studiesinvolving thousands of patients,
few randomized trials have compared this approachwith
standard therapy. Consequently, the use of such treat-
ment in many malignancies isguided bylittle reliable evi-
dence and, in most cases, it is unclear whether it o¡ers
any survival advantage over conventional therapy. This
systematic review was therefore undertaken to appraise
the available published evidence concerning the e¤cacy
of HDT(autol), in a number of key cancers. Although the
review only includes studies reported prior to January
1997, randomized trials published since that time have
supported the results of preliminary analysis and do not
a¡ect the overall conclusions of this review (Santini, Sal-
vagno&Leoni1998;Rodenhuisetal.1998).
As this systematic review is based only on published
t r i a lr e p o r t s ,i tc o u l db es u b j e c tt oan u m b e ro fp o t e n t i a l
biases (Stewart & Parmar1993), including those relating
to unavailable trials, incomplete data and restrictions on
thetype ofanalysesthatcould beperformed. Importantly,
there are a number of closed, but as yet unpublished,
trials that were not available for inclusion in the review
such that publication bias (Dickersin, Min & Meinert
1992) (where the results of positive trials are more likely
to be published than those with`negative'or inconclusive
results)couldbeaproblem.
For no disease site was there su¤cient randomized evi-
dence to determine reliably whether or not HDT(autol)
gives superior overall or progression-free survival com-
pared with CC. For several disease sites only single RCTs
were identi¢ed. These were all small, randomizing
between 45 and109 patients, and were therefore unable
to detect reliably moderate di¡erences in survival and
progression-free survival. Even for those sites where sev-
eral trials were identi¢ed, the total number of patients
randomizedacrossalltrials was still modest. Forexample,
in the consolidation of slow responders in non-Hodgkin's
lymphoma, two trials were identi¢ed that together
included only118 patients. Owing to the small number of
published RCTs and to insu¤cient reporting of data in
trial publications, quantitative synthesis was only possi-
ble in a few instances and the results of these analyses
mustbeviewedwithcaution.
As would be expected from their small size, the results
for overall survival in individual trials are mostly incon-
clusive, although three out of 14 trials that presented
such data reported marginally signi¢cant results (at con-
ventional levels) in favour of HDT. Of the 13 trials that
reported on progression-free survival, eight found signi¢-
cant bene¢t in favour of HDT. Several of the trials were
designed to compare immediate transplantation versus
later transplantation and it is important to consider that
in other trials patients may also have crossed-over from
conventional to HDT.This could reduce the likelihood of
overall survival di¡erences despite improvements in pro-
gression-free survival, and as most reports do not specify
what proportion of patients crossed-over in this way, it is
di¤cult to determine any e¡ect of this strategy. It must,
however, be noted that patients crossing-over from con-
ventionaltreatmenttoHDTandprogenitorcelltransplan-
tation re£ects current clinical practice. Evaluation of
issuessuchasqualityoflife,long-termtoxicityandhealth
economicswillbenecessarytodeterminewhethertrans-
planting early or on relapse is the most appropriate strat-
egy,ifnosurvivaldi¡erence isseen.
Data synthesis was possible only in two disease sites.
For non-Hodgkin's lymphoma the overall ORs for 4-year
survival are inconclusive with the results for ¢rst-line
therapy favouring HDTand those for the consolidationof
¢rst remission favouring CC. On the end-point of progres-
sion-free survival, a combined OR could only be calcu-
lated for ¢rst remission; again this was inconclusive but
favoured HDT. In multiple myeloma the combined OR for
2-year survival favours HDT, but is inconclusive, and for
Autologousstemcelltransplantationformalignancy:areview
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69Table3. Summaryof the economic¢ndingsinthe review
Trial
code
Entry
years
Typeof
transplant
Typeof
evaluation
Costs
included
Method for
determining
total resourcesused
Number
of patients
Cost
(date ofcostassessment
and currency ifavailable)
Costconvertedto
1993 US$
Details of
sensitivityanalysis Comments
Non-Hodgkin's
lymphoma
Uyl-de Groot
et al.(19 9 5 )
Fullpaper
87^93 Autologous Cost-
e¡ectiveness
analysis
** RCT/retrospective 42 (1992)
HDT (autol): $49,983
CC:$15,285
HDT (autol): $51,479
CC:$15,742
Markov model predictions
HDT (autol): $11,132/LYS
$13,016/QALY
CC:$3032/LYS
$3530/QALY
HDT (autol) is more expensiveand did
not improve survival
Dutchstudy
Costs and QALYs discountedat 5%
Costs froma randomizedtrialtaken for
the ¢rst 2 years, thencosts calculated
froma Markov model
Zaidiet al.
(1996)
Abstract
^ Autologous Cost-
e¡ectiveness
analysis
* ^ 11 HDT (autol): $27,000
(£18,000)
CC:$6000(£4000)
HDT (autol): $25,473
CC:$5660
Littleinformation supplied
UK study
Myeloma ^ ¢rst-line therapy
Henon et al.
(1995)
Fullpaper
86^91 Autologous Cost
utility
analysis
** Retrospective
Cox Model
22 (1993)
HDT (autol): $56,700
CC:$46,555
HDT (autol): $56,700
CC: $46,555
^ Patients were treated in France
Di¡erence incost largelyattributableto
intensivetreatment unit
Hodgkin's disease ^ treatment of recurrent disease
Deschet al.
(1992)
Fullpaper
80^91 Autologous Cost
-e¡ectiveness
analysis
** Retrospective
Model
^ HDT (autol): $76,500*
CC$16,300
HDT (autol): $84,577
CC:$18,021
Analysis modelledtransplant usage in
various disease status following
recurrence
*cost for whatwas considered to bethe
optimumtransplant strategy (transplant
in 2nd relapse). Othercosts ranged from
$74,000^110,100
Metastatic breast cancer
Hillneret al.
(1992)
Fullpaper
90^91 Autologous Cost-
e¡ectiveness
analysis
** Markov model ^ (1990)
HDT (autol): $89,700
CC$36,100
HDT (autol): $99,171
CC:$39,911
5%discountingofcosts&bene¢ts
30-yearsurvivaltail reducedcosts by
75%
Clinicaloutcome measures were derived
fromtheliterature
*Procedurecostsonly;**Procedure subsequenttherapy.
CC,conventionalchemotherapy;HDT(autol),high-dosetherapywithautologoustransplantation;LYS,Lifeyearsaved;QALY,Qualityadjustedlifeyears;RCT,randomizedcontrolledtrial.
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02-year progression-free survival a conventionally signi¢-
cantresultinfavourof HDTisobserved.
As discussed in the methods section, there are consid-
erable limitations on the type of analysis possible with a
systematicreviewof theliteraturesuchasthis.Inparticu-
lar, not all trials present su¤cient information to be
included in the analyses, and the time-points for which
these analyses are carried outare constrained by the data
that is presented in trial reports. Consequently, all the
quantitative analyses presented must be interpreted with
caution. As a whole, the review has found no conclusive
evidence that HDT(autol) is superior to conventional
treatment in terms of survival or progression-free survi-
val. Conversely, it has not demonstrated that it is inferior
and, given the overall pattern of results, it appears to be a
therapyworthyoffurtherexploration.
Only one small economic study that used the results of
an RCTas an e¤cacy measure was identi¢ed and it is not
possible to draw conclusions as to the relative cost of
HDT(autol) with CC in any disease site. It is, however,
apparent from non-randomized studies that the relative
costs vary widely between studies and disease sites. It is
probable thatthis relates as muchtothe methodologyand
assumptionsusedincalcul a tin gthecostsastor ealdi¡er-
ences, but until standard analyses are available for com-
parison, health economic assessment may be necessary
forallthevariousdiseasesites.
There is continuing pressure from patients and physi-
cians to broaden the application of HDT and progenitor
cell transplants. At present, despite thousands of patients
havingbeentreated, thereis verylittle reliable evidence of
its e¤cacy. In some malignancies, for instance relapsed
Hodgkin'sdiseaseoraggressivenon-Hodgkin'slymphoma
in second remission, the use of HDT has become so well
established (on the basis of results from non-randomized
studies, or very small randomized trials), that there is
nownorealisticprospectofconductingnewtrialsagainst
conventional therapy. However, for other cancers where
the use of HDT/progenitor transplantation is relatively
new, there is an urgent need for high-quality research to
ensure that any future introduction and use is guided by
reliable evidence. There are at present several ongoing
randomizedtrialsinthediseasesitesinvestigated.Itis cri-
tical to ensure that a su¤ciently high number of patients
are randomized in these studies, and any new studies, to
give su¤cient power to detect moderate di¡erences in
outcome. Where appropriate, these trials should also
incorporateextendedfollow-upinordertoevaluatepossi-
ble long-term toxic e¡ects and economic evaluations,
both of which are currently lacking. More complete
reporting of trial results (ideally using the CONSORT
(Consolidated Standards of Reporting Trials) guidelines;
Begg et al. 1996) is also necessary so that clinical judge-
ments can be made on all the available results of a trial,
not just the highlights. It is worrying that patients are
routinely treated with a therapy whose e¤cacyand long-
term side-e¡ects have yet to be reliably evaluated. The
ideal practice should therefore be to considerentering all
patients for whom autologous transplantation is a treat-
mentoptionintoarandomizedcontrolledtrial.
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